Dogwood Therapeutics (DWTX) Retained Earnings (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Retained Earnings of $195.7 million for Q1 2026, up 330.93% year-over-year from $45.4 million in Q1 2025, and up 6.44% quarter-over-quarter from $183.9 million in Q4 2025.
Dogwood Therapeutics (DWTX) Retained Earnings (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Retained Earnings for 7 consecutive years, with $195.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 330.93% year-over-year to $195.7 million; the TTM figure through Mar 2026 stood at $195.7 million (up 330.93% YoY), while the FY2025 annual figure was $183.9 million, up 4859.44% from the prior year.
- Retained Earnings rose to $195.7 million in Q1 2026 per DWTX's latest filing, from $183.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at $195.7 million in Q1 2026 and bottomed at -$84.7 million in Q1 2025.
- Historically, Retained Earnings has averaged $38.6 million across 5 years, with a median of $64.1 million in 2023.
- On a YoY basis, Retained Earnings climbed as much as 4859.44% in 2025 and fell as far as 228.96% in 2025.
- Dogwood Therapeutics' Retained Earnings stood at -$56.2 million in 2022, then soared by 216.74% to $65.6 million in 2023, then slumped by 105.89% to -$3.9 million in 2024, then jumped by 4859.44% to $183.9 million in 2025, then advanced by 6.44% to $195.7 million in 2026.
- Business Quant data shows DWTX's Retained Earnings at $195.7 million in Q1 2026, $183.9 million in Q4 2025, and $73.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | 196.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 195.70 Mn |
| Dec 31, 2025 | 183.86 Mn |
| Sep 30, 2025 | 73.16 Mn |
| Jun 30, 2025 | 71.00 Mn |
| Mar 31, 2025 | -84.74 Mn |
| Dec 31, 2024 | -3.86 Mn |
| Sep 30, 2024 | 67.34 Mn |
| Jun 30, 2024 | -63.81 Mn |
| Mar 31, 2024 | 65.71 Mn |
| Dec 31, 2023 | 65.58 Mn |
| Sep 30, 2023 | 65.42 Mn |
| Jun 30, 2023 | 64.11 Mn |
| Mar 31, 2023 | -57.69 Mn |
| Dec 31, 2022 | -56.17 Mn |
| Sep 30, 2022 | 63.35 Mn |
| Jun 30, 2022 | -51.55 Mn |
| Mar 31, 2022 | 58.56 Mn |
| Dec 31, 2021 | -43.93 Mn |
| Sep 30, 2021 | 58.29 Mn |
| Jun 30, 2021 | -35.30 Mn |